Paul Tudor Jones Novavax Inc Transaction History

Tudor Investment Corp Et Al

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$3.76 - $6.02 $139,232 - $222,920	37,030 New	37,030 $177,000
Q2 2023 Aug 14, 2023	BUY	$6.67 - $9.52 $81,967 - $116,991	12,289 New	12,289 $91,000
Q4 2022 Feb 14, 2023	BUY	$8.86 - $25.04 $68,168 - $192,657	7,694 Added 19.76%	46,624 $479,000
Q3 2022 Nov 14, 2022	SELL	$18.2 - $76.12 $495,422 - $2.07 Million	-27,221 Reduced 41.15%	38,930 $709,000
Q2 2022 Aug 15, 2022	BUY	$36.28 - $75.29 $685,184 - $1.42 Million	18,886 Added 39.96%	66,151 $3.4 Million
Q1 2022 May 16, 2022	BUY	$69.73 - $142.9 $3.02 Million - $6.2 Million	43,374 Added 1114.73%	47,265 $3.48 Million
Q4 2021 Feb 14, 2022	SELL	$134.56 - $217.97 $702,134 - $1.14 Million	-5,218 Reduced 57.28%	3,891 $557,000
Q3 2021 Nov 15, 2021	SELL	$177.8 - $270.58 $57,607 - $87,667	-324 Reduced 3.43%	9,109 $1.89 Million
Q2 2021 Aug 16, 2021	BUY	$121.0 - $257.67 $1.14 Million - $2.43 Million	9,433 New	9,433 $2 Million

292

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $629M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.